Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study.
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Opat S, et al. Among authors: mckay p. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668. Blood Adv. 2023. PMID: 37682792 Free PMC article. Clinical Trial.
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Gleeson M, Peckitt C, To YM, Edwards L, Oates J, Wotherspoon A, Attygalle AD, Zerizer I, Sharma B, Chua S, Begum R, Chau I, Johnson P, Ardeshna KM, Hawkes EA, Macheta MP, Collins GP, Radford J, Forbes A, Hart A, Montoto S, McKay P, Benstead K, Morley N, Kalakonda N, Hasan Y, Turner D, Cunningham D. Gleeson M, et al. Among authors: mckay p. Lancet Haematol. 2018 May;5(5):e190-e200. doi: 10.1016/S2352-3026(18)30039-5. Lancet Haematol. 2018. PMID: 29703335 Free PMC article. Clinical Trial.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P. Wilson MR, et al. Among authors: mckay p. Blood Adv. 2020 Aug 11;4(15):3586-3593. doi: 10.1182/bloodadvances.2020002421. Blood Adv. 2020. PMID: 32761231 Free PMC article.
Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
Morschhauser F, Tilly H, Chaidos A, McKay P, Phillips T, Assouline S, Batlevi CL, Campbell P, Ribrag V, Damaj GL, Dickinson M, Jurczak W, Kazmierczak M, Opat S, Radford J, Schmitt A, Yang J, Whalen J, Agarwal S, Adib D, Salles G. Morschhauser F, et al. Among authors: mckay p. Lancet Oncol. 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. Epub 2020 Oct 6. Lancet Oncol. 2020. PMID: 33035457 Free PMC article. Clinical Trial.
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J. Opat S, et al. Among authors: mckay p. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15. Clin Cancer Res. 2021. PMID: 34526366 Free PMC article.
Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
Nastoupil LJ, Hess G, Pavlovsky MA, Danielewicz I, Freeman J, García-Sancho AM, Glazunova V, Grigg A, Hou JZ, Janssens A, Kim SJ, Masliak Z, McKay P, Merli F, Munakata W, Nagai H, Özcan M, Preis M, Wang T, Rowe M, Tamegnon M, Qin R, Henninger T, Curtis M, Caces DB, Thieblemont C, Salles G. Nastoupil LJ, et al. Among authors: mckay p. Blood Adv. 2023 Nov 28;7(22):7141-7150. doi: 10.1182/bloodadvances.2023010298. Blood Adv. 2023. PMID: 37722354 Free PMC article. Clinical Trial.
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma.
Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, Kuruvilla J, Montoto S, McKay P, Fox CP, Milliken S, Jiamsakul A, Osborne W, Collins GP, Manos K, Linton KM, Iyengar S, Kassam S, Limei MP, Kliman D, Wong Doo N, Watson AM, Fedele P, Yannakou CK, Hunt S, Ku M, Sehn LH, Smith A, Renshaw H, Maxwell A, Liu Q, Dhairyawan R, Ferguson G, Pickard K, Painter D, Thakrar N, Song KW, Hamad N. Di Ciaccio PR, et al. Among authors: mckay p. Blood. 2024 Jan 11;143(2):152-165. doi: 10.1182/blood.2023021348. Blood. 2024. PMID: 37832030 Free article.
Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline.
Eyre TA, Bishton MJ, McCulloch R, O'Reilly M, Sanderson R, Menon G, Iyengar S, Lewis D, Lambert J, Linton KM, McKay P; Haemato-Oncology Task Force of the British Society for Haematology. Eyre TA, et al. Among authors: mckay p. Br J Haematol. 2024 Jan;204(1):108-126. doi: 10.1111/bjh.19131. Epub 2023 Oct 25. Br J Haematol. 2024. PMID: 37880821 No abstract available.
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, Dickinson M, Prica A, Major A, Hendrickson PG, Hopkins D, Ng A, Casulo C, Baron J, Roberts KB, Al Kendi J, Balogh A, Ricardi U, Torka P, Specht L, De Silva R, Pickard K, Blazin LJ, Henry M, Smith CM, Halperin D, Brady J, Brennan B, Senchenko MA, Reeves M, Hoppe BS, Terezakis S, Talaulikar D, Picardi M, Kirova Y, Fergusson P, Hawkes EA, Lee D, Doo NW, Barraclough A, Cheah CY, Ku M, Hamad N, Mutsando H, Gilbertson M, Marconi T, Viiala N, Maurer MJ, Eichenauer DA, Hoppe RT; GLOW Consortium. Binkley MS, et al. J Clin Oncol. 2024 Mar 26:JCO2301655. doi: 10.1200/JCO.23.01655. Online ahead of print. J Clin Oncol. 2024. PMID: 38531001
Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.
Chaganti S, Maycock S, McIlroy G, Jackson AE, Bishop R, Johnson S, Kanfer E, Kassam S, Cwynarski K, Wrench DJ, Arumainathan A, Fox CP, Johnson RJ, McKay P, Paneesha S, Rowntree C, Balotis C, Collins GP, Davies AJ, Wright J, Burns S Dr, Laurence ADJ, Wheatley K, Menne T. Chaganti S, et al. Among authors: mckay p. Blood. 2024 Apr 21:blood.2024023847. doi: 10.1182/blood.2024023847. Online ahead of print. Blood. 2024. PMID: 38643491
327 results